Global Malignant Melanoma Drug Market & Clinical Pipeline Insight
NEW YORK, Dec. 8, 2016 /PRNewswire/ --
Investigators are trying to develop innovative therapeutics for the treatment of malignant melanoma with high safety and efficacy. Surgery has remained the corner stone of cancer treatment including malignant melanoma. Cancerous region and adjoining tissue is removed to prevent it growth. Radiation therapy is also found to be effective in melanoma treatment but it causes long-tern deleterious effects on body. Chemotherapeutics can prevent malignant cancer but it side effects decrease quality of life and increase morbidity. It has been found that cancerous cells develop changes to evade the effect of the therapeutics leading to less efficacy. These facts are required to be overcome in near future and investigators are trying to develop different modalities. Some progress has been made which is expected to increase the market size of malignant melanoma.
Research and development of malignant melanoma therapeutics has gained lots of attention in past few decades due to rapidly increasing incidences. Large numbers of clinical trials have been instigated to find an effective therapeutics having high safety and efficacy levels. Various products are at different stages of clinical trials which would be introduced in coming years.
Their safety and efficacy is prime concern because investigators are still trying to understand exact mechanism behind factors leading to the development of malignant melanoma. For instance, signaling pathways are complex and intertwined making it difficult for investigators to rely on single approach to treat malignant melanoma. In coming years, it is expected that investigators would be able to identify these factors resulting in development of pharmacologically superior products offering higher safety and efficacy profiles.
Malignant melanoma cells have been found to have changes in genes due to which they spread across the body. It has been found that genes like BRAF are mutated in certain individuals. By blocking their activity it would be possible to prevent the development of malignant melanoma. Side-by-side, identification of aberration in such genes will allow the investigators to identify individuals with high possibility of its development. Physicians would be able to device effective therapeutic strategies to offer better medical care. Several drug target candidates have yet to be discovered and checked for their efficacy against activity of such genes. Blocking of gene activity is difficult as their expression levels keep on changing depending upon physiological activities. Most of the studies are at incipient stages which are expected to take some time in commercialization.
Many innovative therapeutics are at various phases of clinical trials for malignant melanoma treatment. They are expected to generated statistically significant data encouraging pharmaceutical companies to proceed with higher levels of confidence. The long-term effect of these innovative therapeutics is under investigation, sufficiently high safety and efficacy data will make it easy to apply for marketing approval in different countries. In few years, owing to rapidly developing clinical pipelines, innovative malignant melanoma therapeutics are expected to enter in global market leading to increase in their market size. Future commercial success of these novel products seems to be optimistic but their commercialization may take some years.
Read the full report: http://www.reportlinker.com/p04397191-summary/view-report.html
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article